The FDA pushed back the Prescription Drug User Fee Act action date for ruxolitinib cream (Opzelura) by three months to September 19, 2025. The extension will allow regulators time to review additional ...

Investing.com -- BlackRock (NYSE: BLK) Chairman and CEO Larry Fink has expressed support for the Republican proposal to ...

Investing.com -- Tesla (NASDAQ: TSLA) stock pared its gains to 7% from an earlier 10% rise on Monday amid concerns that its ...